Dotinurad is under clinical development by Fortress Biotech and currently in Phase I for Gouty Arthritis (Gout). According to GlobalData, Phase I drugs for Gouty Arthritis (Gout) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dotinurad’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dotinurad (Urece) acts as urate re-absorption agent. It is formulated as tablets for oral route of administration. Urece is indicated for the treatment of gout and hyperuricemia.
Dotinurad (FYU-981) is under development for the treatment of gout and chronic kidney disease. It is administered through oral route as tablet.
Fortress Biotech overview
Fortress Biotech, formerly Coronado Biosciences, identifies, acquires, develops, and commercializes marketed pharmaceuticals and development-stage pharmaceutical product candidates. The company provides business, scientific, regulatory, and legal support for advancing the products or product candidates of its partner firms. It is a marketing partner for various branded drugs indicated for the treatment of radiation dermatitis, severe acne, athlete’s foot, inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and other skin infections. Fortress Biotech is headquartered in New York, the US.
For a complete picture of Dotinurad’s drug-specific PTSR and LoA scores, buy the report here.